Thymosin Alpha-1
Also known as: TA1, Tα1, Thymalfasin, Zadaxin
Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a central role in immune function. It modulates the immune system, enhances T-cell function, and has been used as an adjuvant therapy for various conditions including hepatitis and cancer.
Beginner Basics
Plain-English guide to Thymosin Alpha-1
What it does
This peptide helps boost your immune system by activating immune cells that fight infections and abnormal cells. Researchers use it to support the body's natural defense mechanisms.
Typical dose
Commonly 1.6 mg injected under the skin twice per week, though researchers sometimes use between 0.8 mg and 3.2 mg depending on the study.
When to inject
You can inject in the morning or evening-timing is flexible and won't affect how it works.
Storage
Keep the dry powder in the refrigerator before mixing. After you mix it with liquid, store it in the fridge and use it within a few days.
First-timer tip
This peptide is well-tolerated, so don't worry about severe side effects, and you can use it consistently for extended periods without needing frequent breaks.
On This Page
Research Status
Approved in some countries (not FDA approved in US)
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Mild redness, warmth, or slight swelling at the injection site typically resolves within 1-2 hours. Rotate injection sites to minimize recurrence. Apply ice if needed for comfort.
Low-grade fever (99-100.5°F) may occur within 2-6 hours of injection as the immune system activates. This is typically self-resolving and indicates immune engagement. Acetaminophen or ibuprofen may be used if uncomfortable.
Mild tiredness may occur in the first 24 hours after injection, particularly in the first few doses. This typically diminishes with continued use as the body adapts.
Mild headache may occur within hours of injection. Ensure adequate hydration and rest. Over-the-counter analgesics are appropriate if needed.
Mild nausea is uncommon but may occur, particularly if injected on an empty stomach. Taking the injection with food may help.
Mild myalgia or arthralgias may occur as part of the immune activation response. These typically resolve within 24-48 hours.
Severe allergic reactions (anaphylaxis) are extremely rare but possible. Symptoms include difficulty breathing, facial swelling, severe rash, or throat tightness. Seek immediate medical attention if these occur. Have an epinephrine auto-injector available if you have a history of peptide allergies.
In individuals with pre-existing autoimmune conditions, immune activation may theoretically exacerbate symptoms. Consult with a healthcare provider before use if you have lupus, rheumatoid arthritis, or other autoimmune diseases.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 0.8-3.2 mg |
Frequency, timing and route - members only | |
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 3108 Da |
| Half-life | Approximately 30-60 minutes in circulation; tissue retention extends biological activity |
| Sequence | Members only |
Thymosin Alpha-1 is a naturally occurring peptide that enhances immune function by promoting T-cell maturation and differentiation in the thymus gland, while also activating dendritic cells and macrophages to improve antigen presentation. It acts as an immunomodulator that restores and optimizes both cellular and humoral immune responses, making it particularly useful in conditions where immune function is compromised or dysregulated.
Track your Thymosin Alpha-1 research
Free account. No credit card required.
Recent Research
IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8(+) T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.
Zerumbone mediated CD1d inhibition suppresses epithelial to mesenchymal transition in triple negative breast cancer.
Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Thymosin Alpha-1 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.